

Cefuroxime Formulation

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier		
Trade name	:	Cefuroxime Formulation
Other means of identification	:	Spectrazol Milking Cow (A005270) Coopers Cepravin LC Lactating Cow Intramammary Antibiotic (47941)
1.2 Relevant identified uses of th	e s	substance or mixture and uses advised against
Use of the Sub- stance/Mixture	:	Veterinary product
Recommended restrictions on use	:	Not applicable
1.3 Details of the supplier of the	saf	ety data sheet
Company	:	MSD Kilsheelan Clonmel Tipperary, IE
Telephone	:	353-51-601000
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com
1.4 Emergency telephone numbe	er	

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1

H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

t

Hazard pictograms



Signal word



Cefuroxime Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 10846473-000	
Hazar	d statements	: H334	May cause allergy or asthma symptoms or breath- ing difficulties if inhaled.
Preca	utionary statements	: Response : P304 + P34 P342 + P34	IO IF INHALED: Remove person to fresh air and keep comfortable for breathing.

Hazardous components which must be listed on the label:

Cefuroxime

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.33 %

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		. ,
	Registration number		
Cefuroxime	55268-75-2	Resp. Sens. 1; H334	>= 1 - < 10
	259-560-1	STOT RE 2; H373	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical



Cefuroxime Formulation

Versio 2.5	on	Revision Date: 28.09.2024		DS Number: 9846473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022
				advice.	
Protection of first-aiders		:	and use the recor	ers should pay attention to self-protection, nmended personal protective equipment Il for exposure exists (see section 8).	
If inhaled		:		ive artificial respiration. icult, give oxygen.	
Ir	n case	of skin contact	:	In case of contact, immediately flush skin with soap and plen of water. Get medical attention if symptoms occur.	
In	n case	of eye contact	:		ater as a precaution. tion if irritation develops and persists.
lf	If swallowed		:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.	
4.2 Mc	4.2 Most important symptoms and effects, both acute and delayed				
R	Risks		:	May cause allergy ties if inhaled.	y or asthma symptoms or breathing difficul-
			Excessive exposure may aggravate preexisting asthma a other respiratory disorders (e.g. emphysema, bronchitis, r tive airways dysfunction syndrome).		disorders (e.g. emphysema, bronchitis, reac-
4.3 Inc	dicatio	on of any immediate	me	dical attention and	special treatment needed
Т	reatm	ent	:	Treat symptomati	cally and supportively.
SECT		5: Firefighting meas	sur	es	
5.1 Ex	ctingu	ishing media			
S	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
	Jnsuita nedia	ble extinguishing	:	: None known.	
5.2 Sp	pecial	hazards arising from	the	e substance or mi	xture
S		c hazards during fire-			pustion products may be a hazard to health.
Н	lazard	ous combustion prod-	:	Carbon oxides	



Cefuroxime Formulation

Versio 2.5	on	Revision Date: 28.09.2024		9S Number: 846473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022
L	ucts		Nitrogen oxides (NOx) Sulphur oxides		NOx)
	5.3 Advice for firefighters Special protective equipment : In the event of fire, wear self-contained breathing apparatus				
	for firefighters		•		tective equipment.
	Specific extinguishing meth- ods		:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.	

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	 Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	--

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

SECTION 7: Handling and storage


7.1 Precautions for safe handling Technical measures See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. Local/Total ventilation Use only with adequate ventilation. Do not breathe mist or vapours. Advice on safe handling Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye Hygiene measures flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 7.2 Conditions for safe storage, including any incompatibilities Keep in properly labelled containers. Keep tightly closed. Requirements for storage Store in accordance with the particular national regulations. areas and containers Advice on common storage : Do not store with the following product types: Strong oxidizing agents Gases 7.3 Specific end use(s) Specific use(s) No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Cefuroxime	55268-75-2	TWA	100 µg/m3 (OEB 2)	Internal	
	Further information: RSEN				





Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerides, mixed C8-10 and succinyl	Fresh water	0.0017 mg/l
	Freshwater - intermittent	0.676 mg/l
	Marine water	0.00017 mg/l
	Sewage treatment plant	4.55 mg/kg dry weight (d.w.)
	Fresh water sediment	390.49 mg/kg dry weight (d.w.)
	Marine sediment	39.05 mg/kg dry weight (d.w.)
	Soil	78.01 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	white
		off-white
Odour	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cefuroxime Formulation

Vers 2.5	sion	Revision Date: 28.09.2024		S Number: 346473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022
	Odour ⁻	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial b range	oiling point and boiling	:	No data available	
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	No data available	
	Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	рН		:	No data available	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	No data available	
	Partitio octanol	n coefficient: n- /water	:	Not applicable	
	Vapour	pressure	:	No data available	
	Relative	e density	:	No data available	
	Density	,	:	No data available	
	Relative	e vapour density	:	No data available	
		characteristics icle size	:	Not applicable	
9.2 (Other in Explosi	iformation ves	:	Not explosive	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cefuroxime Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 10846473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022	
Oxidi	zing properties	: The substance	or mixture is not classified as oxidizing.	
Evap	oration rate	: No data availat	ble	
Mole	cular weight	: No data availat	ble	
SECTION	N 10: Stability and I	reactivity		
10.1 Read Not c	c tivity lassified as a reactivity	/ hazard.		
	nical stability e under normal condit	ons.		
10.3 Poss	sibility of hazardous	eactions		
Haza	rdous reactions	: Can react with	strong oxidizing agents.	
10.4 Cond	ditions to avoid			
Cond	litions to avoid	: None known.		
10.5 Inco	mpatible materials			
Mate	Materials to avoid : Oxidizing agents			
	ardous decompositio	•		
No ha	azardous decompositio	on products are known.		
SECTION	N 11: Toxicological	information		
11 1 Infor	mation on hazard cla	usses as defined in Re	egulation (EC) No 1272/2008	
	nation on likely routes			
expo	-	Skin contact		
		Ingestion Eye contact		
Acut	e toxicity			
	lassified based on ava	ilable information.		
<u>Com</u>	ponents:			

Cefuroxime:

Acute oral toxicity	:	LD50 (Rat): > 10,000 mg/kg
		LD50 (Mouse): > 10,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 4,000 mg/kg Application Route: Intravenous
		LD50 (Mouse): > 10,000 mg/kg Application Route: Intravenous

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

LD50 (Rabbit): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefuroxime:

Result

: Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefuroxime:

Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosomal aberration Result: positive
	Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: negative
Genotoxicity in vivo :	Test Type: Micronucleus test Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Cefuroxime Formulation

ersion 5	Revision Date: 28.09.2024	SDS Numl 10846473		Date of last issue: 06.04.2024 Date of first issue: 06.09.2022
Com	ponents:			
Cefu	roxime:			
Effec	ts on fertility	Specie Applica Fertility Sympto		e: Oral 6,400 mg/kg body weight dverse effects
		Applica Fertility		e: Oral 400 mg/kg body weight dverse effects
	F - single exposure lassified based on ava	ilable informa	tion.	
	F - repeated exposur lassified based on ava		tion.	
Com	ponents:			
Cefu	roxime:			
Asse	ssment	: May ca exposu		ge to organs through prolonged or repeated
Repe	ated dose toxicity			
Com	ponents:			
Cefu	roxime:			
Spec NOAI		: Rat : 900 mg	g/kg	

NOAEL Application Route Exposure time Symptoms	 900 mg/kg Subcutaneous 3 M No adverse effects
Species NOAEL LOAEL Application Route Exposure time Target Organs Symptoms	 Dog 400 mg/kg 1,600 mg/kg Oral 27 W Blood Gastrointestinal disturbance
Species NOAEL Application Route Exposure time Target Organs Remarks	 Monkey 450 mg/kg Subcutaneous 1 M Blood, Urinary tract May cause damage to organs.



Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Cefuroxime:		
General Information	: Repeated contact may cause allergic reactions in very sus ceptible persons.	;-
Inhalation	: Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, co	olitis

SECTION 12: Ecological information

12.1 Toxicity

Components:		
Cefuroxime:		
Ecotoxicology Assessment Acute aquatic toxicity	:	Toxic effects cannot be excluded
Chronic aquatic toxicity	:	Toxic effects cannot be excluded
 12.2 Persistence and degradabili No data available 12.3 Bioaccumulative potential 	ty	
Components:		
Cefuroxime: Partition coefficient: n- octanol/water	:	log Pow: -0.429
12.4 Mobility in soil		
No data available		
12.5 Results of PBT and vPvB as	se	ssment
Product:		



Cefuroxime Formulation

Version 2.5	Revision Date: 28.09.2024		DS Number: 0846473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022	
Assessment		:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.		
12.6 Endo	ocrine disrupting prop	ertie)S		
Prod	uct:				
	ssment	:	The substance/mixture does not contain components consid ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 a levels of 0.1% or higher.		
	er adverse effects ata available				
SECTION	N 13: Disposal consi	der	ations		
13.1 Was	te treatment methods				
Prod	uct	:	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.		

		discussion with the waste disposal authorities.
		Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Cefuroxime Formulation

Versio 2.5	n Revision Date: 28.09.2024		0S Number: 846473-00007	Date of last issue: 06.04.2024 Date of first issue: 06.09.2022			
14.3 T	ransport hazard class(es)						
Α	DN	:	Not regulated as	a dangerous good			
Α	DR	:	Not regulated as a	a dangerous good			
R	ID	:	Not regulated as a dangerous good				
IN	MDG	:	Not regulated as a	a dangerous good			
IA	ATA	:	Not regulated as a	a dangerous good			
14.4 P	Packing group						
Α	DN	:	Not regulated as	a dangerous good			
Α	DR	:	Not regulated as	a dangerous good			
R	ID	:	Not regulated as	a dangerous good			
IN	MDG	:	Not regulated as a	a dangerous good			
IA	ATA (Cargo)	:	Not regulated as a	a dangerous good			
IA	ATA (Passenger)	:	Not regulated as a	a dangerous good			
14.5 Environmental hazards Not regulated as a dangerous good							
14.6 Special precautions for user Not applicable							
14.7 N	laritime transport in bulk a	acco	ording to IMO inst	ruments			
R	emarks	:	Not applicable for	product as supplied.			

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable



Cefuroxime Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 10846473-00007		f last issue: 06.04.2024 f first issue: 06.09.2022
•	lation (EU) 2019/1021 c (recast)	on persistent organic p	ollu- :	Not applicable
ment	lation (EU) No 649/201: and the Council concer ngerous chemicals		Not applicable	
REACH - List of substances subject to authorisation (Annex XIV)				Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the contr major-accident hazards involving dangerous substances. Not applicable				

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information	
Other information :	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements	
H334 :	May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.
H373 :	May cause damage to organs through prolonged or repeated exposure.
Full text of other abbreviations	
Resp. Sens. : STOT RE :	Respiratory sensitisation Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good La-



Cefuroxime Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.5	28.09.2024	10846473-00007	Date of first issue: 06.09.2022

boratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

H334

Classification of the mixture:

Resp. Sens. 1

Calculation method

Classification procedure:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN